Background: On October 22, 2020, the antiviral drug Remdesivir was approved by the United States Food and Drugs Authority (US FDA) for use in adults and pediatric patients for the treatment of COVID-19 requiring hospitalization. It was observed that Remdesivir and steroids have been used in treating moderate to severe COVID-19 patients. But there is very little evidence to justify which out of the two is a more rational approach towards treating patients infected with COVID-19 Disease. Objective: This study observes the pattern of the duration of stay in patients treated only with Remdesivir compared to those treated in combination with steroids. Method: This retrospective study included patients hospitalized due to COVID-19 between March 2020 to June 2021 with appropriate ICD-10 CM diagnosis recorded in Optum’s de-identified claims database. The total identified patients were divided in two cohorts, one being the patients treated with Remdesivir alone and another in combination with steroids (Methylprednisolone or Dexamethasone). We then calculated the average length of stay in both groups. We would further analyze the effect these measures had on the ICU stay and need for ventilatory support. Result: A total of 40,807 patients were identified who were either treated with Remdesivir only or in combination with Steroids. The Remdesivir only Cohort consisted of 30,392 patients whereas the one in combination had 10,415 patients. The average length of stay for Remdesivir alone was calculated as 11.36 whereas the average length of stay for patients who were treated in combination with steroids was 7.54. Conclusion: The study observed that patients treated in combination with steroids had comparatively shorter average length of stay in comparison to those who were treated with Remdesivir alone. Further analysis needs to be done to compare the outcome of these measures on the ICU stay and the need for ventilatory support.